PL2300452T3 - 5-[5-[2-(3,5-Bis(trifluorometylo)fenylo)-2-metylopropanoilometyloamino]-4-(4-fluoro-2-metylofenylo)]-2-pirydynylo-2-alkilo-prolinoamidy jako antagonisty receptora NK1 - Google Patents

5-[5-[2-(3,5-Bis(trifluorometylo)fenylo)-2-metylopropanoilometyloamino]-4-(4-fluoro-2-metylofenylo)]-2-pirydynylo-2-alkilo-prolinoamidy jako antagonisty receptora NK1

Info

Publication number: PL2300452T3
Authority: PL; Poland
Prior art keywords: methylpropanoylmethylamino; prolinamide; pyridinyl; methylphenyl; trifluoromethyl
Prior art date: 2008-05-14

Application number

PL09745725T

Other languages

English (en)

Inventor

Giuseppe Alvaro

Agostino Marasco

Original Assignee

Nerre Therapeutics Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-05-14

Filing date

2009-05-12

Publication date

2014-04-30

2009-05-12 Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd

2014-04-30 Publication of PL2300452T3 publication Critical patent/PL2300452T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Addiction (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Transplantation (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Nutrition Science (AREA)

PL09745725T 2008-05-14 2009-05-12 5-[5-[2-(3,5-Bis(trifluorometylo)fenylo)-2-metylopropanoilometyloamino]-4-(4-fluoro-2-metylofenylo)]-2-pirydynylo-2-alkilo-prolinoamidy jako antagonisty receptora NK1 PL2300452T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0808747.0A GB0808747D0 (en)	2008-05-14	2008-05-14	Novel compounds
EP09745725.3A EP2300452B1 (en)	2008-05-14	2009-05-12	5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
PCT/EP2009/055700 WO2009138393A1 (en)	2008-05-14	2009-05-12	5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists

Publications (1)

Publication Number	Publication Date
PL2300452T3 true PL2300452T3 (pl)	2014-04-30

Family

ID=39571329

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09745725T PL2300452T3 (pl)	2008-05-14	2009-05-12	5-[5-[2-(3,5-Bis(trifluorometylo)fenylo)-2-metylopropanoilometyloamino]-4-(4-fluoro-2-metylofenylo)]-2-pirydynylo-2-alkilo-prolinoamidy jako antagonisty receptora NK1

Country Status (22)

Country	Link
US (4)	US20090286836A1 (pl)
EP (1)	EP2300452B1 (pl)
JP (1)	JP5465716B2 (pl)
KR (1)	KR101567116B1 (pl)
CN (1)	CN102105458B (pl)
AR (1)	AR071721A1 (pl)
AU (1)	AU2009248102B8 (pl)
BR (1)	BRPI0911990B1 (pl)
CA (1)	CA2724219C (pl)
CL (1)	CL2009001146A1 (pl)
DK (1)	DK2300452T3 (pl)
EA (1)	EA019037B1 (pl)
ES (1)	ES2446866T3 (pl)
GB (1)	GB0808747D0 (pl)
IL (1)	IL209197A (pl)
MX (1)	MX2010012421A (pl)
PE (1)	PE20091847A1 (pl)
PL (1)	PL2300452T3 (pl)
TW (1)	TWI444376B (pl)
UY (1)	UY31824A (pl)
WO (1)	WO2009138393A1 (pl)
ZA (1)	ZA201007904B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8426450B1 (en) *	2011-11-29	2013-04-23	Helsinn Healthcare Sa	Substituted 4-phenyl pyridines having anti-emetic effect
JP5806420B1 (ja)	2013-11-08	2015-11-10	キッセイ薬品工業株式会社	カルボキシメチルピペリジン誘導体
TWI649307B (zh) *	2014-05-07	2019-02-01	日商橘生藥品工業股份有限公司	Cyclohexylpyridine derivative
WO2016021562A1 (ja) *	2014-08-06	2016-02-11	キッセイ薬品工業株式会社	シアノチオフェン誘導体
WO2018197638A1 (en)	2017-04-27	2018-11-01	Nerre Therapeutics Limited	Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide
EP4096508A4 (en) *	2020-01-30	2024-03-27	Javed, Mohammad	COMBINATION THERAPIES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
AU2021285503A1 (en)	2020-06-02	2022-12-08	Nerre Therapeutics Limited	Neurokinin (NK)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000050398A2 (en)	1999-02-24	2000-08-31	F. Hoffmann-La Roche Ag	Phenyl- and pyridinyl derivatives as neurokinin 1 antagonists
DE60014216T2 (de)	1999-02-24	2006-03-02	F. Hoffmann-La Roche Ag	4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
US6303790B1 (en)	1999-11-29	2001-10-16	Hoffman-La Roche Inc.	Process for the preparation of pyridine derivatives
SI1303490T1 (sl)	2000-07-14	2008-10-31	Hoffmann La Roche	N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
TWI287003B (en)	2000-07-24	2007-09-21	Hoffmann La Roche	4-phenyl-pyridine derivatives
TWI259180B (en)	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
AU2002250876B2 (en)	2001-04-23	2005-03-03	F. Hoffmann-La Roche Ag	Use of NK-1 receptor antagonists against benign prostatic hyperplasia
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en)	2001-07-31	2005-02-01	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted amides
NZ544244A (en) *	2003-07-03	2008-10-31	Hoffmann La Roche	Dual NK1/NK3 antagonists for treating schizophrenia
DE602005026669D1 (de)	2004-07-06	2011-04-14	Hoffmann La Roche	Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
US20060030600A1 (en) *	2004-08-06	2006-02-09	Patrick Schnider	Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP5121716B2 (ja) *	2005-09-09	2013-01-16	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	ピリジン誘導体および精神異常の処置におけるそれらの使用
ATE472529T1 (de) *	2005-10-10	2010-07-15	Glaxo Group Ltd	Prolinamidderivate als natriumkanalmodulatoren

2008
- 2008-05-14 GB GBGB0808747.0A patent/GB0808747D0/en not_active Ceased
2009
- 2009-05-12 KR KR1020107027927A patent/KR101567116B1/ko active IP Right Grant
- 2009-05-12 CL CL2009001146A patent/CL2009001146A1/es unknown
- 2009-05-12 WO PCT/EP2009/055700 patent/WO2009138393A1/en active Application Filing
- 2009-05-12 MX MX2010012421A patent/MX2010012421A/es active IP Right Grant
- 2009-05-12 JP JP2011508893A patent/JP5465716B2/ja active Active
- 2009-05-12 DK DK09745725.3T patent/DK2300452T3/da active
- 2009-05-12 CA CA2724219A patent/CA2724219C/en active Active
- 2009-05-12 UY UY0001031824A patent/UY31824A/es not_active Application Discontinuation
- 2009-05-12 ES ES09745725.3T patent/ES2446866T3/es active Active
- 2009-05-12 US US12/464,171 patent/US20090286836A1/en not_active Abandoned
- 2009-05-12 CN CN2009801275140A patent/CN102105458B/zh active Active
- 2009-05-12 PE PE2009000650A patent/PE20091847A1/es not_active Application Discontinuation
- 2009-05-12 AU AU2009248102A patent/AU2009248102B8/en not_active Ceased
- 2009-05-12 BR BRPI0911990-6A patent/BRPI0911990B1/pt active IP Right Grant
- 2009-05-12 US US12/991,515 patent/US8344005B2/en active Active
- 2009-05-12 EP EP09745725.3A patent/EP2300452B1/en active Active
- 2009-05-12 EA EA201071299A patent/EA019037B1/ru not_active IP Right Cessation
- 2009-05-12 AR ARP090101713A patent/AR071721A1/es not_active Application Discontinuation
- 2009-05-12 PL PL09745725T patent/PL2300452T3/pl unknown
- 2009-05-12 TW TW098115612A patent/TWI444376B/zh not_active IP Right Cessation
2010
- 2010-11-04 ZA ZA2010/07904A patent/ZA201007904B/en unknown
- 2010-11-08 IL IL209197A patent/IL209197A/en active IP Right Grant
2012
- 2012-11-20 US US13/681,925 patent/US8822504B2/en active Active
2014
- 2014-05-16 US US14/280,280 patent/US9006271B2/en active Active

Also Published As

Publication number	Publication date
US9006271B2 (en)	2015-04-14
CA2724219A1 (en)	2009-11-19
IL209197A0 (en)	2011-01-31
CN102105458A (zh)	2011-06-22
TW201006813A (en)	2010-02-16
US20140249188A1 (en)	2014-09-04
CL2009001146A1 (es)	2010-09-24
DK2300452T3 (da)	2014-02-17
JP2011520834A (ja)	2011-07-21
EA201071299A1 (ru)	2011-06-30
ES2446866T3 (es)	2014-03-10
KR20110017384A (ko)	2011-02-21
US8822504B2 (en)	2014-09-02
UY31824A (es)	2009-11-10
ZA201007904B (en)	2011-11-30
TWI444376B (zh)	2014-07-11
CN102105458B (zh)	2013-06-12
AU2009248102B8 (en)	2012-07-26
CA2724219C (en)	2016-04-05
PE20091847A1 (es)	2010-01-09
EP2300452B1 (en)	2013-11-20
BRPI0911990B1 (pt)	2021-07-13
IL209197A (en)	2014-09-30
US8344005B2 (en)	2013-01-01
MX2010012421A (es)	2011-03-25
BRPI0911990A2 (pt)	2020-08-18
KR101567116B1 (ko)	2015-11-06
JP5465716B2 (ja)	2014-04-09
EA019037B1 (ru)	2013-12-30
AU2009248102B2 (en)	2012-06-28
US20130143931A1 (en)	2013-06-06
WO2009138393A1 (en)	2009-11-19
US20090286836A1 (en)	2009-11-19
EP2300452A1 (en)	2011-03-30
US20110060015A1 (en)	2011-03-10
GB0808747D0 (en)	2008-06-18
AR071721A1 (es)	2010-07-07
AU2009248102A1 (en)	2009-11-19

Publication	Publication Date	Title
EP2349262A4 (en)	2012-08-29	ANTAGONISTS CARBOXAMIDE PHENYL 2,5-DISUBSTITUTED OREXIN RECEPTOR
IL209197A0 (en)	2011-01-31	5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
EP2349270A4 (en)	2012-04-25	2,5-DISUBSTITUTED MORPHOLINE OREXIN RECEPTOR ANTAGONISTS
EP2349269A4 (en)	2012-04-25	2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
EP2350066A4 (en)	2012-06-27	2,5-DISUBSTITUTED PIPERIDINES AS ANTAGONISTS OF THE OREXIN RECEPTOR
IL195511A0 (en)	2009-09-01	1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]
BRPI0914772A2 (pt)	2015-10-20	compostos heterocíclicos 1,2-dissubstituídos
ATE509928T1 (de)	2011-06-15	8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ZA201001221B (en)	2011-04-28	1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
EP2244576A4 (en)	2011-06-08	1,3-OXAZOLIDIN-2-ONE 3,5-SUBSTITUTED DERIVATIVES
HK1147674A1 (en)	2011-08-19	Heterocyclic compounds as crth2 receptor antagonists crth2
IL219718A0 (en)	2012-07-31	3-(3-,4- dihydro-2h-benzo [1,4] oxazin - 6 yl) 1h-pyrimidin -2, 4 dione compounds as herbicides
HK1199450A1 (en)	2015-07-03	2,5-disubstituted arylsulfonamide ccr3 antagonists 25- ccr3
ZA201003909B (en)	2011-11-30	Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
IL194549A0 (en)	2009-08-03	2-(pyridin-2-yl)-pyrimidines for use as fungicides
IL215727A0 (en)	2012-01-31	2,5-disubstituted arylsulfonamide ccr3 antagonists
AP2010005512A0 (en)	2010-12-31	Novel compounds active as muscarinic receptor antagonists.
IL195027A0 (en)	2009-08-03	Constrained compounds as cgrp-receptor antagonists
EP2365748A4 (en)	2012-05-02	IMIDAZOISOINDOLA ANTAGONISTS OF NEUROPEPTIDE S RECEPTORS
ZA200809205B (en)	2010-01-27	Constrained compounds as CGRP-receptor antagonists
PL2029716T3 (pl)	2017-04-28	Stała kompozycja do pielęgnacji tkanin oparta na mydle
ZA200705852B (en)	2009-12-30	2-OXO-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-ylpiperidines used as CGRP antagonists
IL185640A0 (en)	2008-01-06	Use of 2-anilino-3 ,4-dihydro-quinazolines as 5ht5a receptor antagonists
IL208917A0 (en)	2011-01-31	Spiro (piperidine-4,2-pyrolidine)-1-(3,5-trifluoromethyl phenyl) methylcarboxamides as nk1 tachikynin receptor antagonists
EP2069339A4 (en)	2010-01-20	SUBSTITUTED PIPERIDINOPHENYLOXAZOLIDINONE